The Delphion Integrated View

Title: **JP10087484A2: USE OF ISOXAZOLE AND CROTONAMIDE DERIVATIVE FOR MODULATION OF APOPTOSIS**
[Derwent Title]

Country: JP Japan
Kind: A

Inventor: **MUELLNER STEFAN DR;**
DAX CLAUDIA DCH;



View Image

1 page

Assignee: **HOECHST AG**
News, Profiles, Stocks and More about this company

Published / Filed: **1998-04-07** / 1997-07-30

Application Number: **JP1997000204344**

IPC Code: **A61K 31/275;** A61K 31/41; A61K 31/42; A61K 31/42; A61K 31/42; A61K 31/42; A61K 31/42; A61K 31/42; A61K 31/42; A61K 31/435; A61K 31/445; A61K 45/00; C07D 213/40; C07D 213/75; C07D 263/34; C07D 413/12;

Priority Number: 1996-10-01 DE1996019640555

Abstract:

PROBLEM TO BE SOLVED: To obtain a pharmaceutical agent capable of exhibiting modulation effect even on apoptosis by using a compound having an action to inhibit the dephosphorylation of cophylline as an active component.

SOLUTION: This agent contains at least one kind of substance selected from a compound of the formula I and/or the formula II (R1 is a 1-4C alkyl, a 3-5C cycloalkyl, etc.; R2 is CF3, O-CF3, S-CF3, OH, etc.; R3 is a 1-4C alkyl, a halogen or H; X is CH or N atom) and/or its optical steric isomer and/or its physiologically permissible salt. The compound of the formula I or II is e.g. N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide. The administration rate of the compound of the formula I and/or the formula II is preferably 2-250mg, especially 10-50mg. The agent is expected to be useful for the treatment of infarction, fit, transplantation, autoimmune diseases, etc.

COPYRIGHT: (C)1998,JPO

INPADOC Legal Status: None Buy Now: Family Legal Status Report

Designated Country: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Family: Show 7 known family members

Other Abstract Info: CHEMABS 128(15)176182M DERABS C98-112057